presentation
HIV Prevention R&D at Risk
AVAC’s analysis of the impact of US Government funding cuts, terminated projects, and other policy changes on the HIV prevention research and development (R&D) pipeline, and on HIV research broadly.
Accelerating Product Innovation and Availability
Improving how prevention is delivered
Developing a rich pipeline of options for HIV prevention is essential and must be guided by community priorities that define what products are needed and supported through R&D.
Once approved, interventions typically become widely available in wealthy countries within a few years time. But scaling up new options in lower and middle-income countries lags for years, even decades, with devastating effects on global health, individual lives, and the global effort to end the epidemic.
AVAC’s work supports:
- Development of timely, effective and affordable prevention options
- Including community needs and perspectives in R&D
- Getting products faster to market and to scale
- Understanding the products’ users
- Compiling and analyzing market data
- Sharing information
- Bringing effective prevention options to those who need them
- Advocating for the integration of HIV services with sexual and reproductive health
What's New
report
Gears of Lenacapavir for PrEP Rollout
This document outlines a focused plan for LEN for PrEP rollout over the next few years, specifying priorities by stakeholder and evaluating volume and pricing strategies. The report as a whole details a coordinated response to this historic opportunity to ensure rapid implementation, equitable access, and sustainable impact.
infographic
The Future of ARV-Based Prevention and More
The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of MPTs in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.
An Overview of Lenacapavir for PrEP Trials
The PURPOSE trials evaluate the safety and efficacy of injectable lenacapavir (LEN), an investigational antiretroviral (ARV) drug being studied as a potential PrEP product. This graphic shows the latest status of all five trials including the groundbreaking results of PURPOSE 1 and PURPOSE 2.
Related Projects
Dual Prevention Pill Project
Integrating PrEP and contraception in a single pill to expand choices.
PrEPWatch
A one-stop online clearinghouse for resources and information to help the global community effectively deliver proven methods of PrEP to everyone who needs it.
Coalition to Accelerate Access to Long-Acting PrEP
Overcoming access challenges to new PrEP options.
The Latest on Accelerating Product Innovation
Embracing Task Shifting and Innovation to Support Expanded Access to Long-Acting Injectable PrEP
While the HIV prevention buffet will soon offer a second form of long acting injectable PrEP, ensuring access to all those who can benefit requires innovations in service delivery such as task shifting. In the United States, two Federally Qualified Health Centers (FQHCs) have implemented programming that has expanded clinic capacity, resulting in more individuals being able to choose long acting injectable PrEP. We will also hear about innovative efforts to expand PrEP access in South Africa. Learn what it takes to integrate task shifting for LAI PrEP injection programs, and join in the discussion on other ways we can collectively innovate to support expanded, sustainable access to all forms of PrEP.
AVAC Condemns Removal of the Advisory Committee on Immunization Practices
AVAC strongly condemns Secretary of Health and Human Services, Robert F. Kennedy, Jr., for removing all members of the Advisory Committee on Immunization Practices (ACIP). This committee of vaccine experts—with decades of experience in vaccine development, delivery and safety—is responsible for developing the country’s vaccine policies and recommendations for the CDC.
The Scientific Journey of Lenacapavir — and the Urgency to Defend HIV Prevention Science
On June 11, AVAC hosted a conversation, The Scientific Journey of Lenacapavir: From basic science to clinical development to impact, to explore how US support from NIH for basic science and South Africa’s clinical research infrastructure made possible the development of lenacapavir for PrEP (LEN), a discovery in HIV prevention that went on to be named Science magazine’s 2024 Breakthrough of the Year.
As the field anticipates initial regulatory approval from the US FDA by June 19 and a WHO recommendation in July, Linda-Gail Bekker of the Desmond Tutu Health Foundation, Wes Sundquist of the University of Utah and Mitchell Warren of AVAC underscored how this moment of promise is threatened by sweeping attacks on science, research and the very systems that made the development of LEN possible.